ProShare Advisors
ITOS

ProShare Advisors’s iTeos Therapeutics ITOS Stock Holding History

ProShare Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,138
Closed -$262K – 1955
2022
Q1 		$262K Sell
8,138
-1,244
-13% -$45.2K ﹤0.01% 1729
2021
Q4 		$437K Sell
9,382
-728
-7% -$24.2K ﹤0.01% 1552
2021
Q3 		$273K Sell
10,110
-1,437
-12% -$37.6K ﹤0.01% 1613
2021
Q2 		$296K Buy
11,547
+1,424
+14% +$33.9K ﹤0.01% 1905
2021
Q1 		$346K Buy
10,123
+2,237
+28% +$80.8K ﹤0.01% 1707
2020
Q4 		$267K Buy
+7,886
New +$209K ﹤0.01% 1685

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ProShare Advisors's ITOS Position: Q2 2022 in Review

ProShare Advisors sold out of iTeos Therapeutics (ITOS) in Q2 2022, closing a stake of 8,138 shares — an estimated $262K sold.

ProShare Advisors first reported a position in ITOS in Q4 2020 and held it in 6 quarters. The position peaked at $437K in Q4 2021. 152 funds tracked by Wall St. Rank hold ITOS as of Q2 2022.

  • ProShare Advisors reported no remaining iTeos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 8,138 iTeos Therapeutics shares in Q2 2022, an estimated $262K.
  • ProShare Advisors first reported a position in iTeos Therapeutics in Q4 2020 and held it in 6 quarters.
  • ProShare Advisors's iTeos Therapeutics position peaked at $437K in Q4 2021.
  • 152 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.